VEGF signaling inhibitors: More pro-apoptotic than anti-angiogenic

Cancer and Metastasis Reviews

Volumn 26, Issue 3-4, 2007, Pages 443-452

  Epstein, Richard J ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Angiogenesis; Apoptosis; Bevacizumab; Chemosensitization; Permeability

Indexed keywords

BEVACIZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; VASCULOTROPIN INHIBITOR;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; AUTOCRINE EFFECT; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL SURVIVAL; CHEMOSENSITIZATION; CLINICAL PRACTICE; CYTOTOXICITY TEST; DOWN REGULATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HYPOXIA; MICROMETASTASIS; NONHUMAN; OUTCOME ASSESSMENT; PARACRINE SIGNALING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR CELL; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 36148950966     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-007-9071-1     Document Type: Review

References (148)

1. Warren, B. A., & Shubik, P. (1966). The growth of the blood supply to melanoma transplants in the hamster cheek pouch. Laboratory Investigation, 15(2), 464-478.
2. Skalak, T. C. (2005). Angiogenesis and microvascular remodeling: A brief history and future roadmap. Microcirculation, 12(1), 47-58.
3. Folkman, J. (1971). Tumor angiogenesis: Therapeutic implications. New England Journal of Medicine, 285(21), 1182-1186.
4. Haller, J. S. Jr. (1986). Decline of bloodletting: A study in 19th-century ratiocinations. Southern Medical Journal, 79(4), 469-475.
5. Morabia, A. (2006). Pierre-Charles-Alexandre Louis and the evaluation of bloodletting. Journal of the Royal Society of Medicine, 99(3), 158-160.
6. Voogt, P. J., et al. (1987). Perioperative blood transfusion and cancer prognosis. Different effects of blood transfusion on prognosis of colon and breast cancer patients. Cancer, 59(4), 836-843.
7. Maeta, M., et al. (1994). Perioperative allogeneic blood transfusion exacerbates surgical stress-induced postoperative immunosuppression and has a negative effect on prognosis in patients with gastric cancer. Journal of Surgical Oncology, 55(3), 149-153.
8. Azuma, C., et al. (1997). The influence of peri-operative blood transfusion during radical hysterectomy on the prognosis of uterine cervical cancer. Transfusion Science, 18(1), 55-62.
9. Nosotti, M., et al. (2003). Correlation between perioperative blood transfusion and prognosis of patients subjected to surgery for stage I lung cancer. Chest, 124(1), 102-107.
10. Leyland-Jones, B., et al. (2005). Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. Journal of Clinical Oncology, 23(25), 5960-5972.
11. Henke, M., et al. (2003). Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet, 362(9392), 1255-1260.
12. Henke, M., et al. (2006). Do erythropoietin receptors on cancer cells explain unexpected clinical findings? Journal of Clinical Oncology, 24(29), 4708-4713.
13. Pajonk, F., et al. (2004). The erythropoietin-receptor pathway modulates survival of cancer cells. Oncogene, 23(55), 8987-8991.
14. Yasuda, Y., et al. (2003). Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis, 24(6), 1021-1029.
15. Watanabe, D., et al. (2005). Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. New England Journal of Medicine, 353(8), 782-792.
16. Belenkov, A. I., et al. (2004). Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Molecular Cancer Therapeutics, 3(12), 1525-1532.
17. Harris, S. R., et al. (2002). Tumor growth enhancing effects of vascular endothelial growth factor are associated with increased nitric oxide synthase activity and inhibition of apoptosis in human breast carcinoma xenografts. Cancer Letters, 179(1), 95-101.
18. Argraves, W. S., & Drake, C. J. (2005). Genes critical to vasculogenesis as defined by systematic analysis of vascular defects in knockout mice. The Anatomical Record. Part A, Discoveries in Molecular, Cellular, and Evolutionary Biology, 286(2), 875-884.
19. Gottfried, O. N., et al. (2004). Embolization of metastatic spinal tumors. Neurosurgery Clinics of North America, 15(4), p. 391-399.
20. Edwards, R. D., et al. (2007). Uterine-artery embolization versus surgery for symptomatic uterine fibroids. New England Journal of Medicine, 356(4), 360-370.
21. Fortin, A., et al. (1999). Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy. Journal of Clinical Oncology, 17(1), 101-109.
22. Nielsen, H. M., et al. (2006). Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: Long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. Journal of Clinical Oncology, 24(15), 2268-2275.
23. Clarke, M., et al. (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet, 366(9503), 2087-2106.
24. Ceelen, W., et al. (2006). Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model. International Journal of Radiation Oncology, Biology, Physics, 64(4), 1188-1196.
25. Nakamura, R., et al. (2003). Iridium-192 brachytherapy for hemorrhagic angiosarcoma of the scalp: A case report. Japanese Journal of Clinical Oncology, 33(4), 198-201.
26. Biswal, B. M., et al. (1995). Hemostatic radiotherapy in carcinoma of the uterine cervix. International Journal of Gynaecology and Obstetrics, 50(3), 281-285.
27. Inai, T., et al. (2004). Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. American Journal of Pathology, 165(1), 35-52.
28. Mancuso, M. R., et al. (2006). Rapid vascular regrowth in tumors after reversal of VEGF inhibition. Journal of Clinical Investigation, 116(10), 2610-2621.
29. Yamazaki, Y., & Morita, T. (2006). Molecular and functional diversity of vascular endothelial growth factors. Molecular Diversity, 10(4), 515-527.
30. Rahimi, N. (2006). VEGFR-1 and VEGFR-2: Two non-identical twins with a unique physiognomy. Frontiers in Bioscience, 11, 818-829.
31. Baulida, J., et al. (1996). All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. Journal of Biological Chemistry, 271(9), 5251-5257.
32. Waterman, H., et al. (1999). The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing. European Molecular Biology Organization Journal, 18(12), 3348-3358.
33. Sithanandam, G., et al. (2005). Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549. Oncogene, 24(11), 1847-1859.
34. Holbro, T., et al. (2003). The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proceedings of the National Academy of Sciences of the United States of America, 100(15), 8933-8938.
35. Brogi, E., et al. (1994). Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation, 90(2), 649-652.
36. Hose, C., et al. (2005). Transcriptional profiling identifies altered intracellular labile iron homeostasis as a contributing factor to the toxicity of adaphostin: Decreased vascular endothelial growth factor secretion is independent of hypoxia-inducible factor-1 regulation. Clinical Cancer Research, 11(17), 6370-6381.
37. Markel, T., et al. (2007). Iron chelation stimulates fetal human intestinal cell production of IL-6 and VEGF while decreasing HGF: The roles of p38, ERK and JNK/MAPK signaling. American Journal of Physiology: Gastrointestinal and Liver Physiology, DOI 10.1152/ajpgi.00502.2006.
38. Shi, Y. H., et al. (2005). In vitro study of HIF-1 activation and VEGF release by bFGF in the T47D breast cancer cell line under normoxic conditions: Involvement of PI-3K/Akt and MEK1/ERK pathways. Journal of Pathology, 205(4), 530-536.
39. Mani, N., et al. (2005). Astrocyte growth effects of vascular endothelial growth factor (VEGF) application to perinatal neocortical explants: Receptor mediation and signal transduction pathways. Experimental Neurology, 192(2), 394-406.
40. Petit, A. M., et al. (1997). Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. American Journal of Pathology, 151(6), 1523-1530.
41. Mathur, R. S., & Mathur, S. P. (2005). Vascular endothelial growth factor (VEGF) up-regulates epidermal growth factor receptor (EGF-R) in cervical cancer in vitro: This action is mediated through HPV-E6 in HPV-positive cancers. Gynecologic Oncology, 97(1), 206-213.
42. Salcedo, R., et al. (1999). Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. American Journal of Pathology, 154(4), 1125-1135.
43. Epstein, R. J. (2004). The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nature Reviews. Cancer, 4(11), 901-909.
44. Oda, Y., et al. (2006). CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: Analysis within a group of patients, all of whom developed lung metastasis. Modern Pathology, 19(5), 738-745.
45. Lordick, F., et al. (2006). Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: Report of three cases. International Journal of Radiation Oncology, Biology, Physics, 64(5), 1295-1298.
46. Traina, T. A., et al. (2006). Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer. Oncologist, 11(10), 1070-1071.
47. Franco, M., et al. (2006). Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Research, 66(7), 3639-3648.
48. Nakamura, K., et al. (2006). KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Research, 66(18), 9134-9142.
49. Baeten, C. I., et al. (2006). Effects of radiotherapy and chemotherapy on angiogenesis and leukocyte infiltration in rectal cancer. International Journal of Radiation Oncology, Biology, Physics, 66(4), 1219-1227.
50. Albertsson, P., Lennernas, B., & Norrby, K. (2006). On metronomic chemotherapy: Modulation of angiogenesis mediated by VEGE-A. Acta Oncológica, 45(2), 144-155.
51. Drevs, J., et al. (2004). Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Research, 24(3a), 1759-1763.
52. Guo, X. L., et al. (2003). Inhibitory effects of docetaxel on expression of VEGF, bFGF and MMPs of LS174T cell. World Journal of Gastroenterology, 9(9), 1995-1998.
53. Miller, J. W. (1997). Vascular endothelial growth factor and ocular neovascularization. American Journal of Pathology, 151(1), 13-23.
54. Weis, S. M., & Cheresh, D. A. (2005). Pathophysiological consequences of VEGF-induced vascular permeability. Nature, 437(7058), 497-504.
55. Bates, D. O., & Harper, S. J. (2002). Regulation of vascular permeability by vascular endothelial growth factors. Vascular Pharmacology, 39(4-5), 225-237.
56. Rosenfeld, P. J., et al. (2006). Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine, 355(14), 1419-1431.
57. Kerbel, R. S. (2006). Antiangiogenic therapy: A universal chemosensitization strategy for cancer? Science, 312(5777), 1171-1175.
58. Salnikov, A. V., et al. (2006). Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma. International Journal of Cancer, 119(12), 2795-2802.
59. Wedam, S. B., et al. (2006). Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. Journal of Clinical Oncology, 24(5), 769-777.
60. Preda, A., et al. (2004). MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer. Journal of Magnetic Resonance Imaging, 20(5), 865-873.
61. Osusky, K. L., et al. (2004). The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis, 7(3), 225-233.
62. Wang, Y., et al. (2004). Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis, 7(4), 335-345.
63. Inan, S., et al. (2006). Immunolocalizations of VEGF, its receptors flt-1, KDR and TGF-beta's in epithelial ovarian tumors. Histology and Histopathology, 21(10), 1055-1064.
64. Xia, G., et al. (2006). Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. Journal of Urology, 175(4), 1245-1252.
65. Seto, T., et al. (2006). Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer, 53(1), 91-96.
66. Karp, J. E., et al. (2004). Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: Therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clinical Cancer Research, 10(11), 3577-3585.
67. Kharfan-Dabaja, M. A., et al. (2006). Expression of the vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukemia: Incidence and feasibility of immunohistochemical staining. Clinical and Laboratory Haematology, 28(4), 254-258.
68. Spitzer, M. S., et al. (2006). Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. British Journal of Ophthalmology, 90(10), 1316-1321.
69. Vaupel, P., Thews, O., & Hoeckel, M. (2001). Treatment resistance of solid tumors: Role of hypoxia and anemia. Medical Oncology, 18(4), 243-259.
70. Thomas, G. M. (2002). Raising hemoglobin: An opportunity for increasing survival? Oncology, 63(2), 19-28.
71. Littlewood, T. J. (2001). The impact of hemoglobin levels on treatment outcomes in patients with cancer. Seminars in Oncology, 28(2 Suppl 8), 49-53.
72. Wu, Y., et al. (2006). The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. International Journal of Cancer, 119(7), 1519-1529.
73. Graells, J., et al. (2004). Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. Journal of Investigative Dermatology, 123(6), 1151-1161.
74. Mercurio, A. M., Lipscomb, E. A., & Bachelder, R. E. (2005). Non-angiogenic functions of VEGF in breast cancer. Journal of Mammary Gland Biology and Neoplasia, 10(4), 283-290.
75. Sergina, N. V., et al. (2007). Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature, 445(7126), 437-441.
76. Wu, Y., et al. (2006). Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clinical Cancer Research, 12(21), 6573-6784.
77. Jain, R. K., et al. (2006). Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Clinical Practice Oncology, 3(1), 24-40.
78. Krause, S., et al. (2005). Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and cisplatin. Journal of Urology, 174(1), 328-331.
79. Kyzas, P. A., et al. (2005). Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2. Modern Pathology, 18(4), 485-494.
80. Schoeffner, D. J., et al. (2005). VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms. Laboratory Investigation, 85(5), 608-623.
81. Weigand, M., et al. (2005). Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis, 8(3), 197-204.
82. Higgins, K. J., et al. (2006). Vascular endothelial growth factor receptor-2 expression is induced by 17beta-estradiol in ZR-75 breast cancer cells by estrogen receptor alpha/Sp proteins. Endocrinology, 147(7), 3285-3295.
83. Wu, J., et al. (2004). Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: Preferential regulation by progesterone receptor B. Cancer Research, 64(6), 2238-2244.
84. Luwor, R. B., et al. (2005). The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene, 24(27), 4433-4441.
85. Klos, K. S., et al. (2006). ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Research, 66(4), 2028-2037.
86. Linderholm, B., et al. (2004). Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment. European Journal of Cancer, 40(1), 33-42.
87. Dragowska, W. H., et al. (2004). HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization. Molecular Cancer Research, 2(11), 606-619.
88. Lesslie, D. P., et al. (2006). Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. British Journal of Cancer, 94(11), 1710-1717.
89. Wey, J. S., et al. (2005). Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer, 104(2), 427-438.
90. Curigliano, G., et al. (2005). Systemic effects of surgery: Quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery. Breast Cancer Research and Treatment, 93(1), 35-40.
91. Yoon, S. S., et al. (2006). Profile of plasma angiogenic factors before and after hepatectomy for colorectal cancer liver metastases. Annals of Surgical Oncology, 13(3), 353-362.
92. Brieger, J., et al. (2005). Vascular endothelial growth factor and basic fibroblast growth factor are released by squamous cell carcinoma cells after irradiation and increase resistance to subsequent irradiation. International Journal of Molecular Medicine, 16(1), 159-164.
93. Chung, Y. L., et al. (2006). Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: Implications for radiotherapy of hepatocellular carcinoma. Clinical Cancer Research, 12(9), 2706-2715.
94. Lev, D. C., et al. (2004). Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. Journal of Clinical Oncology, 22(11), 2092-2100.
95. Furstenberger, G., et al. (2006). Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. British Journal of Cancer, 94(4), 524-531.
96. Kuethe, F., et al. (2005). Treatment with granulocyte colony-stimulating factor for mobilization of bone marrow cells in patients with acute myocardial infarction. American Heart Journal, 150(1), 115.
97. Shani-Peretz, H., et al. (2005). HVEGF165 increases survival of transplanted hepatocytes within portal radicles: Suggested mechanism for early cell engraftment. Cell Transplant, 14(1), 49-57.
98. Indraccolo, S., et al. (2006). Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment. Proceedings of the National Academy of Sciences of the United States of America, 103(11), 4216-4221.
99. Wild, R., et al. (2004). Carboplatin selectively induces the VEGF stress response in endothelial cells: Potentiation of antitumor activity by combination treatment with antibody to VEGF. International Journal of Cancer, 110(3), 343-351.
100. Tonra, J. R., et al. (2006). Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clinical Cancer Research, 12(7 Pt 1), 2197-2207.
101. Herbst, R. S., et al. (2005). Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. Journal of Clinical Oncology, 23(11), 2544-2555.
102. Sandler, A., & Herbst, R. (2006). Combining targeted agents: Blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clinical Cancer Research, 12(14 Pt 2), 4421s-4425s.
103. Brazelle, W. D., Shi, W., & Siemann, D. W. (2006). VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy. International Journal of Radiation Oncology, Biology, Physics, 65(3), 836-841.
104. Roberts, N., et al. (2006). Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Research, 66(5), 2650-2657.
105. Hirakawa, S., et al. (2006). VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood, 109(3):1010-1017.
106. Hoshida, T., et al. (2006). Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: Therapeutic implications. Cancer Research, 66(16), 8065-8075.
107. Des Guetz, G., et al. (2006). Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. British Journal of Cancer, 94(12), 1823-1832.
108. Ek, E. T., et al. (2006). Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma? Oncology Reports, 16(1), 17-23.
109. Bolat, F., et al. (2006). Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: Correlations with prognostic parameters. Journal of Experimental & Clinical Cancer Research, 25(3), 365-372.
110. Ravi, D., et al. (2001). Apoptosis, angiogenesis and proliferation: Trifunctional measure of tumour response to radiotherapy for oral cancer. Oral Oncology, 37(2), 164-171.
111. Gadducci, A., et al. (2003). Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma. Anticancer Research, 23(1B), 549-556.
112. Callagy, G., et al. (2000). Immunohistochemical measurement of tumor vascular endothelial growth factor in breast cancer. A more reliable predictor of tumor stage than microvessel density or serum vascular endothelial growth factor. Applied Immunohistochemistry & Molecular Morphology, 8(2), 104-109.
113. Bairey, O., et al. (2000). Microvessel density in chemosensitive and chemoresistant diffuse large B-cell lymphomas. Medical Oncology, 17(4), 314-318.
114. Jubb, A. M., et al. (2006). Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. Journal of Clinical Oncology, 24(2), 217-227.
115. Yoon, S. S., et al. (2004). Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma. Annals of Oncology, 15(8), 1261-1266.
116. Foekens, J. A., et al. (2001). High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Research, 61(14), 5407-5414.
117. Ogata, Y., et al. (2006). The expression of vascular endothelial growth factor determines the efficacy of post-operative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. Oncology Reports, 15(5), 1111-1116.
118. Manders, P., et al. (2004). Vascular endothelial growth factor levels do not predict efficacy of systemic adjuvant treatment as assessed in 1127 breast cancer patients. International Journal of Oncology, 25(2), 511-517.
119. Zhukova, L. G., Zhukov, N. V., & Lichinitser, M. R. (2003). Expression of Flt-1 and Flk-1 receptors for vascular endothelial growth factor on tumor cells as a new prognostic criterion for locally advanced breast cancer. Bulletin of Experimental Biology and Medicine, 135(5), 478-481.
120. Giatromanolaki, A., et al. (2006). Phosphorylated KDR expression in endometrial cancer cells relates to HIF1alpha/VEGF pathway and unfavourable prognosis. Modern Pathology, 19(5), 701-707.
121. Denlinger, C. E., Rundall, B. K., & Jones, D. R. (2005). Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo. Journal of Thoracic and Cardiovascular Surgery, 130(5), 1422-1429.
122. Gong, W., et al. (2005). Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clinical Cancer Research, 11(4), 1386-1393.
123. Zhang, W., et al. (2005). Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation. Leukemia, 19(11), 1977-1984.
124. Nishimura, R., et al. (2003). Higher plasma vascular endothelial growth factor levels correlate with menopause, overexpression of p53, and recurrence of breast cancer. Breast Cancer, 10(2), 120-128.
125. Kamat, C. D., et al. (2006). Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia. Cancer Letters, 249(2), 209-219.
126. Fleming, J. B., et al. (2005). Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: Justification for K-ras-directed therapy. Molecular Cancer Research, 3(7), 413-423.
127. Stearns, M., et al. (2005). Activated Ras enhances insulin-like growth factor I induction of vascular endothelial growth factor in prostate epithelial cells. Cancer Research, 65(6), 2085-2088.
128. Pore, N., et al. (2003). PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Research, 63(1), 236-241.
129. Longley, D. B., & Johnston, P. G. (2005). Molecular mechanisms of drug resistance. Journal of Pathology, 205(2), 275-292.
130. 0-phase cells during induction chemotherapy correlates with subsequent remission in acute myeloid leukemia. International Journal of Hematology, 71(3), 249-255.
131. Tsuruo, T., et al. (2003). Molecular targeting therapy of cancer: Drug resistance, apoptosis and survival signal. Cancer Science, 94(1), 15-21.
132. Bidus, M. A., et al. (2006). Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. Gynecologic Oncology, 102(1), 5-7.
133. Eto, M., & Naito, S. (2006). Molecular targeting therapy for renal cell carcinoma. International Journal of Clinical Oncology, 11(3), 209-213.
134. Balasubramanian, L., & Evens, A. M. (2006). Targeting angiogenesis for the treatment of sarcoma. Current Opinion in Oncology, 18(4), 354-359.
135. Epstein, R. J., & Leung, T. W. (2007). Reversing hepatocellular carcinoma progression by using networked biological therapies. Clinical Cancer Research, 13(1), 11-17.
136. Catalano, A., Gianni, W., & Procopio, A. (2004). Experimental therapy of malignant mesothelioma: New perspectives from anti-angiogenic treatments. Critical Reviews in Oncology/Hematology, 50(2), 101-109.
137. Cairo, M. S. (2000). Dose reductions and delays: Limitations of myelosuppressive chemotherapy. Oncology (Williston Park), 14(9 Suppl 8), 21-31.
138. Kligman, L., et al. (2004). The treatment of lymphedema related to breast cancer: A systematic review and evidence summary. Support Care Cancer, 12(6), 421-431.
139. Haritoglou, C., et al. (2006). Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina, 26(9), 999-1005.
140. Finger, P. T. (2007). Anti-VEGF bevacizumab (Avastin(R)) for radiation optic neuropathy. American Journal of Ophthalmology, 143(2), 335-338.
141. Gonzalez, J., et al. (2007). Effect of bevacizumab on radiation necrosis of the brain. International Journal of Radiation Oncology, Biology, Physics, 67(2), 323-326.
142. Grosios, K., et al. (2004). Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis. Inflammation Research, 53(4), 133-142.
143. Mehlen, P., & Puisieux, A. (2006). Metastasis: A question of life or death. Nature Reviews. Cancer, 6(6), 449-458.
144. Mohsin, S. K., et al. (2005). Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. Journal of Clinical Oncology, 23(11), 2460-2468.
145. Joensuu, H., et al. (2006). Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. New England Journal of Medicine, 354(8), 809-820.
146. Stambolic, V., & Woodgett, J. R. (2006). Functional distinctions of protein kinase B/Akt isoforms defined by their influence on cell migration. Trends in Cell Biology, 16(9), 461-466.
147. Townson, J. L., & Chambers, A. F. (2006). Dormancy of solitary metastatic cells. Cell Cycle, 5(16), 1744-1750.
148. Epstein, R. J. (2005). Maintenance therapy to suppress micrometastasis: The new challenge for adjuvant cancer treatment. Clinical Cancer Research, 11(15), 5337-5341.